Join Us

Sign up to join a global movement of people working together to end the injustice of poverty.

By submitting above you agree to the Oxfam America privacy policy.

Thank you for joining!

Want us to keep you updated by text message? Provide us with your mobile phone number.

By submitting above you agree to the Oxfam America privacy policy.

Welcome to our community!

We’ll provide you with information and tools you need to take on the injustice of poverty.

Close

Sign up to join a global movement of people working to end the injustice of poverty.

We can do this.

You’re smart, passionate, and care about people. We do too. Let’s join forces and end poverty—sign up for our emails today.

Thank you for joining

Want us to keep you updated by text message? Provide us with your mobile phone number.

Please enter a valid mobile phone number

Welcome to our community

We’ll provide you with information and tools you need to take on the injustice of poverty.

Reaction to Pfizer/BioNTech South African Licensing Agreement

By

In response to the announcement that Pfizer/BioNTech will start to manufacture vaccines under license via a South African manufacturer, with the aim of producing 100 million doses for distribution exclusively in Africa - the first of which will be produced in 2022, Robbie Silverman, Oxfam America’s Senior Advocacy Manager and spokesperson for the People’s Vaccine Alliance, said:

“While this announcement is good news, it is simply not enough. To date, Pfizer has sold over 90 percent of their vaccines to rich nations only, while doctors and nurses are dying daily all over the developing world. Africa is facing a shortfall of hundreds of millions of vaccines now and these South African made doses won’t start to be available until next year.

“This also proves that the argument pharmaceutical companies have consistently made about developing countries not having the capacity or skills to be able to make vaccines is a myth.

“Charity and largely symbolic measures by corporations will not deliver vaccines for everyone, everywhere. Only by sharing the technology and dramatically increasing manufacturing around the world, will we be able to finally gain the upper hand on the pandemic.”

Share this article:

Press contact

For more information, contact:

Laura Rusu
Associate Director of Media
Washington, DC
Office: (202) 496-1169
Cell: (202) 459-3739
Email: [email protected]

Oxfam.org Facebook Twitter Instagram YouTube Google+